All In Biotech

NDA 218171 · Xcovery

Ensacove

Ensartinib Hydrochloride · Oral

Novel

CDER novel approval, Dec 18, 2024: To treat non-small cell lung cancer

Last checked: Nov 20, 2026Latest source record: Feb 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Dec 18, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

36

3 Phase 3, 5 recruiting

FAERS reports

45

34 serious, 5 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 17, 2026.

ENSACOVE is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)as detected by an FDA-approved test [see Dosage and Administration ( 2.1 )] who have not previously received an ALK-inhibitor. ENSACOVE is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test who have not previously received an ALK-inhibitor. ( 1 , 2.1 )

Mechanism: Ensartinib is a kinase inhibitor of anaplastic lymphoma kinase (ALK) and inhibits other kinases including MET and ROS1. In vitro, ensartinib inhibited phosphorylation of ALK and its downstream signaling proteins AKT, ERK, and S6, thereby blocking ALK-mediated signaling pathways and inhibiting proliferation in cell lines harboring ALK fusions and mutations. In vivo, ensartinib showed anti-tumor activity in a mouse xenograft model of human NSCLC harboring an ALK fusion.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 18, 2024 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
2 products under this application
  • ENSACOVE · ENSARTINIB HYDROCHLORIDE EQ 25MG BASE · CAPSULE, ORAL · Prescription
  • ENSACOVE · ENSARTINIB HYDROCHLORIDE EQ 100MG BASE · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ensartinib" as an intervention, any sponsor and status, largest first.

All 36 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • rash9
  • pruritus7
  • constipation6
  • drug ineffective5
  • fatigue5
  • death4
  • disease progression4
  • oedema4
  • adverse event3
  • product use issue3
  • rash pruritic3
  • alanine aminotransferase increased2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20212
20224
20232
20246
20253
202628

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 28 on PubMed

Sponsor: Xcovery

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.